Vanoxerine was originally developed as a dopamine transporter antagonist for the treatment of depression and Parkinson’s disease, but later failed todemonstrate significant benefit for these diseases (Lane et al. 2005; Spealman et al. 1989; Howell and Byrd 1991; Howell and Landrum 1997; Nagase et al. 1991; Giros et al. 1992). The gene discussed is SLC6A3; the disease is depressive symptom measurement.